Pharmasset selects PSI-879 as nucleotide analogue inhibitor of hepatitis C for preclinical development

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Motorola Mobility Notifies Certain Purchasers of Refurbished Motorola...
DNR Commemorates Conservation Officer's Death, Honors His...
Campaign tackles domestic violence ahead of Six Nations...
Justice Department Announces Luke J...
City of Lansing's River Trail closed at the M-43/Saginaw Street...
Michigan Liquor Control Commission Offers Tips on How to Host a...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Pharmasset selects PSI-879 as nucleotide analogue inhibitor of hepatitis C for preclinical development
6 October 2009 - US clinical-stage pharmaceutical company Pharmasset Inc (NASDAQ: VRUS) said today it has nominated PSI-352879 (PSI-879) as a second development candidate from two series of purine analogues for the treatment of chronic hepatitis C virus (HCV) infection.
PSI-879 is a...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search